Inogen, Inc · NASDAQ:INGN
Inogen — Investor Presentation (January 2020)
23 slides from Inogen's investor presentation, Jan 13, 2020
Slide 1: Company Overview January 2020
Company Overview January 2020 Exhibit 99.2 [INOGEN LOGO] OXYGEN. ANYTIME. ANYWHERE.
Slide 2: Notice regarding forward-looking statements
Notice regarding forward-looking statements These slides and the accompanying oral presentation (the “Presentation”) include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based
Slide 3: Inogen POC offers freedom and mobility
Inogen POC offers freedom and mobility Stationary oxygen concentrator + Regular oxygen tank delivery Delivery Model Inogen Model 2.8 pounds (single battery) Run time up to 5 hours with a double battery A/C adaptable Conforms to all applicable FAA requirements Suitable for overnight use Portable oxyg
Slide 4: Traditional O2 therapy challenged by market dynamics
Traditional O2 therapy challenged by market dynamics Traditional O2 P Inogen Cost effective Maximizes mobility P P O O O Relevance today >50% reduction to Medicare reimbursement rates Oxygen delivery has high infrastructure and variable costs Ambulatory O2 à 2x survival; 60% fewer hospital days1 Uti
Slide 5: Product performance drives leadership position
Product performance drives leadership position Inogen One G5® Inogen One G4® Inogen One G3® Launch Date April 2019 May 2016 September 2012 Minimum Advertised Retail Price $2,395 $2,295 $2,295 O2 capacity 1,260 ml/min 630 ml/min 1,050 ml/min Overnight ü ü ü Single Solution ü ü ü User Replaceable Batt
Slide 6: Building the Inogen brand
Building the Inogen brand Targeted advertising Consumer preference Domestic direct-to-consumer sales ($M) Domestic business-to-business sales ($M) +48% 3-year CAGR Founded in patient preference +50% 3-year CAGR [inogen logo] OXYGEN. ANYTIME. ANYWHERE.6
Slide 7: U.S. market dynamics continue to favor POC adoption by traditional HME providers
U.S. market dynamics continue to favor POC adoption by traditional HME providers Estimated Penetration of POCs1 Average total monthly Medicare reimbursement in CBAs Note 1: Based on 2018 U.S. Medicare claims data and our estimates of the ratio of the Medicare market to the total market. Value exclud
Slide 8: Tidal Assist Ventilator (TAV)
Tidal Assist ® Ventilator (TAV ®) Non-invasive ventilator (NIV) for select patients with chronic lung diseases (Rx required) Compatible with certain oxygen concentrators, oxygen cylinders, wall gas, and certain medical air sources Delivers higher flow and pressure versus traditional oxygen therapy P
Slide 9: Strategic value of New Aera Acquisition
Strategic value of New Aera Acquisition Complementary [inogen logo] OXYGEN. ANYTIME. ANYWHERE.9 Sales Opportunity Enhances Financial Profile Strengthens Technology Leadership Expansion into NIV Market
Slide 10: Benefits of TAV vs standard oxygen
Benefits of TAV® vs standard oxygen The trial was a randomized, open-label crossover study comparing TAV vs. standard oxygen for its impact on exercise endurance, oxygen saturation, and Borg dyspnea 18 subjects included moderate to very severe COPD or interstitial lung disease patients studied at a
Slide 11: Globally diversified revenue
Globally diversified revenue Sales in 47 countries Growing worldwide revenue 2018 Revenue: $358.1M 2019 Preliminary Unaudited Revenue¹: $361.9M ¹2019 estimated revenue of $361.9M based on the midpoint of preliminary, unaudited revenue range provided in the Company’s press release dated January 13, 2
Slide 12: Historical Revenue
Historical Revenue Revenue ($M) 11 Year CAGR of 39% based on 2020 guidance2 ¹2019 estimated revenue of $361.9M based on the midpoint of preliminary, unaudited revenue range provided in the Company’s press release dated January 13, 2020 of $361.4M - $362.4M. This outlook represents the Company’s guid
Slide 13: Balance sheet overview
Balance sheet overview [Insert object title] Cash, cash equivalents & marketable securities on hand $200.6M Debt $0.0M No additional capital requirements to meet current operating plan Net positive cash flow Maximizes flexibility 2020 Expectations1 12020 expectations are based on guidance provided i
Slide 14: Multiple avenues to drive future revenue growth
Multiple avenues to drive future revenue growth Direct-to-consumer expansion Increase domestic & international B2B adoption 329 inside sales reps* 20 outside physician sales & support team members* Focusing on sales rep productivity & scaling sales and rental intake teams 9 U.S. B2B sales & support
Slide 15: Company highlights
Company highlights Market leader in large, global, underpenetrated market DTC model enables innovation and customer access Differentiated product portfolio with commitment to R&D Seasoned management team with proven track record Attractive financial profile [inogen logo] OXYGEN. ANYTIME. ANYWHERE.15
Slide 16: Proprietary and [inogen logo]
Proprietary and Confidential [inogen logo]
Slide 17: Supplemental Information January 2020
Supplemental Information January 2020 [inogen logo] OXYGEN. ANYTIME. ANYWHERE.
Slide 18: 510(k) clearance by the FDA and key regulatory approvals
510(k) clearance by the FDA FDA registered manufacturing facilities Conforms to all applicable FAA requirements for use on commercial aircraft Quality Management System certified to comply with ISO 13485 for the design, development, manufacture, distribution and service of oxygen concentrators, non-
Slide 19: Estimated U.S. Medicare penetration of portable oxygen concentrators
Estimated U.S. Medicare penetration of portable oxygen concentrators We believe POCs remain under penetrated Based on 2018 U.S. Medicare claims data, ambulatory patients account for 76% of total LTOT patients. Inogen estimates a full POC penetration rate to be 90% of the existing ambulatory patient
Slide 20: Design expertise & intellectual property
Design expertise & intellectual property 46 patents issued System design and assembly Control systems for oxygen concentrators and ventilators Nasal interface designs Sieve bed designs and life prediction 26 pending patent applications POC design improvements Ventilation interface design Design feat
Slide 21: Average non-delivery ambulatory monthly rates
Average non-delivery ambulatory monthly rates 233 136 134 We believe lower reimbursement rates will drive conversion to non-delivery solutions, although there are challenges to HME provider adoption short-term POC reimbursement rates are an 18% premium compared to stationary+tanks in 36-mo rental pe
Slide 22: Continuous innovation to stay at the forefront of customer preference
Continuous innovation to stay at the forefront of customer preference 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 inogen one inogen one g2 inogen one g3 inogen at home inogen one g4 inogen one g5 tav oct 2004 release June 2006 update April 2009 update march 2
Slide 23: A proven team built for success
A proven team built for success Ali Bauerlein Chief Financial Officer, Executive Vice President, Finance, Corporate Secretary & Corporate Treasurer Scott Wilkinson President, Chief Executive Officer, BOD Member Co-founder of Inogen with over 18 years experience in treasury, finance, accounting, risk